Healthcare provider profile · identity verified

Ryan T Trauring, DO

Internal Medicine · KOKOMO, IN · NPI 1700900016

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	589	131
Atorvastatin Calcium	Atorvastatin Calcium	466	122
Rosuvastatin Calcium	Rosuvastatin Calcium	458	136
Pantoprazole Sodium	Pantoprazole Sodium	313	91
Losartan Potassium	Losartan Potassium	299	85
Amlodipine Besylate	Amlodipine Besylate	273	72
Metformin Hcl	Metformin Hcl	218	69
Omeprazole	Omeprazole	216	67
Escitalopram Oxalate	Escitalopram Oxalate	206	51
Lisinopril	Lisinopril	197	56
Gabapentin	Gabapentin	193	52
Tamsulosin Hcl	Tamsulosin Hcl	174	47
Jardiance	Empagliflozin	156	36
Metoprolol Succinate	Metoprolol Succinate	148	43
Hydrochlorothiazide	Hydrochlorothiazide	139	36
Trazodone Hcl	Trazodone Hcl	139	36
Simvastatin	Simvastatin	137	38
Tramadol Hcl	Tramadol Hcl	135	21
Potassium Chloride	Potassium Chloride	115	26
Pioglitazone Hcl	Pioglitazone Hcl	112	30
Meloxicam	Meloxicam	111	30
Trulicity	Dulaglutide	107	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	103	32
Pravastatin Sodium	Pravastatin Sodium	98	25
Olmesartan Medoxomil	Olmesartan Medoxomil	94	29
Allopurinol	Allopurinol	92	27
Mounjaro	Tirzepatide	87	19
Montelukast Sodium	Montelukast Sodium	83	26
Diclofenac Sodium	Diclofenac Sodium	80	22
Albuterol Sulfate Hfa	Albuterol Sulfate	79	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	76	18
Alprazolam	Alprazolam	73	19
Citalopram Hbr	Citalopram Hydrobromide	69	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	68	21
Zolpidem Tartrate	Zolpidem Tartrate	68	24
Furosemide	Furosemide	67	19
Sertraline Hcl	Sertraline Hcl	67	20
Bupropion Xl	Bupropion Hcl	66	14
Metoprolol Tartrate	Metoprolol Tartrate	63	17
Topiramate	Topiramate	60	14
Duloxetine Hcl	Duloxetine Hcl	57	14
Metformin Hcl Er	Metformin Hcl	57	14
Ozempic	Semaglutide	56	suppressed
Celecoxib	Celecoxib	55	suppressed
Ezetimibe	Ezetimibe	54	18
Hydroxyzine Hcl	Hydroxyzine Hcl	53	17
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	49	14
Lorazepam	Lorazepam	46	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	45	11
Famotidine	Famotidine	45	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	45	12
Oxybutynin Chloride Er	Oxybutynin Chloride	44	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	42	30
Carvedilol	Carvedilol	40	12
Ropinirole Hcl	Ropinirole Hcl	40	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	40	suppressed
Alendronate Sodium	Alendronate Sodium	39	suppressed
Valsartan	Valsartan	38	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	36	suppressed
Pregabalin	Pregabalin	36	suppressed
Spironolactone	Spironolactone	36	11
Synthroid	Levothyroxine Sodium	36	suppressed
Ondansetron Odt	Ondansetron	35	suppressed
Glipizide Er	Glipizide	34	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Buspirone Hcl	Buspirone Hcl	31	suppressed
Nebivolol Hcl	Nebivolol Hcl	31	suppressed
Eliquis	Apixaban	30	suppressed
Propranolol Hcl Er	Propranolol Hcl	30	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	29	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	29	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	23
Fluticasone Propionate	Fluticasone Propionate	29	12
Finasteride	Finasteride	28	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	28	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	28	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Januvia	Sitagliptin Phosphate	27	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Colestipol Hcl	Colestipol Hcl	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Clonazepam	Clonazepam	24	suppressed
Diazepam	Diazepam	24	suppressed
Linzess	Linaclotide	23	suppressed
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	21	18
Fenofibrate	Fenofibrate	21	suppressed
Humalog Kwikpen U-100	Insulin Lispro	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	21
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Atenolol	Atenolol	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Methylprednisolone	Methylprednisolone	19	18
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Raloxifene Hcl	Raloxifene Hcl	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Cephalexin	Cephalexin	18	11
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Glimepiride	Glimepiride	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Risperidone	Risperidone	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Febuxostat	Febuxostat	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	17	suppressed
Azithromycin	Azithromycin	16	15
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Glipizide	Glipizide	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	15
Levetiracetam	Levetiracetam	15	suppressed
Myrbetriq	Mirabegron	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Naproxen	Naproxen	14	suppressed
Nurtec Odt	Rimegepant Sulfate	14	suppressed
Prednisone	Prednisone	14	14
Primidone	Primidone	14	suppressed
Ranolazine Er	Ranolazine	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	suppressed
Testosterone Cypionate	Testosterone Cypionate	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Nexium	Esomeprazole Magnesium	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	13	suppressed
Armour Thyroid	Thyroid,pork	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Bydureon Bcise	Exenatide Microspheres	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Icosapent Ethyl	Icosapent Ethyl	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Baclofen	Baclofen	11	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	11	suppressed
Budesonide Er	Budesonide	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error